PreciseDx raised $20.7M in a Series B funding led by Eventide Asset Management to advance its AI-based breast cancer risk assessment.

Aug 21, 2024•11 months ago

Amount Raised

$20.7 Million

Round Type

series b

New YorkScience And EngineeringData And AnalyticsHealth Care

Investors

Gen Henn Capital VentureQuest DiagnosticsLabcorpEventide Asset Management

Description

Cancer diagnostics startup PreciseDx secured $20.7 million in Series B funding to boost its commercialization efforts for an AI-driven breast cancer risk assessment. The round was supported by notable investors including Labcorp, Quest Diagnostics, and GenHenn Capital Venture.

Company Information

Company

PreciseDx

Location

New York, New York, United States

About

PreciseDx is a leading innovator in AI-powered, patient-specific disease analysis. PreciseDx’s Morphology Feature Array™ provides clinical teams with unmatched information and accurate, actionable intelligence for disease state characterization, supporting personalized patient management.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

PreciseDx raised $20.7M in a Series B funding led by Eventide Asset Management to advance its AI-based breast cancer risk assessment.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information